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Abstract
The transcription factor ATF2 has been shown to attenuate melanoma susceptibility to apoptosis and to promote its ability
to form tumors in xenograft models. To directly assess ATF2’s role in melanoma development, we crossed a mouse
melanoma model (Nras
Q61K::Ink4a
2/2) with mice expressing a transcriptionally inactive form of ATF2 in melanocytes. In
contrast to 7/21 of the Nras
Q61K::Ink4a
2/2 mice, only 1/21 mice expressing mutant ATF2 in melanocytes developed
melanoma. Gene expression profiling identified higher MITF expression in primary melanocytes expressing transcriptionally
inactive ATF2. MITF downregulation by ATF2 was confirmed in the skin of Atf2
2/2 mice, in primary human melanocytes, and
in 50% of human melanoma cell lines. Inhibition of MITF transcription by MITF was shown to be mediated by ATF2-JunB–
dependent suppression of SOX10 transcription. Remarkably, oncogenic BRAF (V600E)–dependent focus formation of
melanocytes on soft agar was inhibited by ATF2 knockdown and partially rescued upon shMITF co-expression. On
melanoma tissue microarrays, a high nuclear ATF2 to MITF ratio in primary specimens was associated with metastatic
disease and poor prognosis. Our findings establish the importance of transcriptionally active ATF2 in melanoma
development through fine-tuning of MITF expression.
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Introduction
Malignant melanoma is one of the most highly invasive and
metastatic tumors [1], and its incidence has been increasing at a
higher rate than other cancers in recent years [2]. Significant
advances in understanding melanoma biology have been made
over the past few years, thanks to identification of genetic changes
along the MAPK signaling pathway. Those include mutations in
BRAF, NRAS, KIT and GNAQ, all of which result in a constitutively
active MAPK pathway [3–5]. Consequently, corresponding
transcription factor targets such as microphthalmia-associated
transcription factor (MITF) [6], AP2 [7], and C-JUN [8] and its
heterodimeric partner ATF2 [9] are activated and induce changes
in cellular growth, motility and resistance to external stress
[10,11]. In addition, constitutively active MAPK/ERK causes
rewiring of other signaling pathways [4]. Among examples of
rewired signaling is upregulation of C-JUN expression and activity
[8], which potentiates other pathways, including PDK1, AKT and
PKC, and plays a critical role in melanoma development [12].
Activating transcription factor 2 (ATF2), a member of the bZIP
family, is activated by stress kinases including JNK and p38 and is
implicated in transcriptional regulation of immediate early genes
regulating stress and DNA damage responses [13–15] and
expression of cell cycle control proteins [16]. To activate
transcription, ATF2 heterodimerizes with bZIP proteins, including
C-JUN and CREB [17,18], both of which are constitutively
upregulated in melanomas [8]. ATF2 is also implicated in the DNA
damage response through phosphorylation by ATM/ATR [19].
Knock-in mice expressing a form of ATF2 that cannot be
phosphorylated by ATM are more susceptible to tumor develop-
ment [20]. Nuclear localization of ATF2 in melanoma tumor cells is
associated with poor prognosis [21], likely due to transcriptional
activity of constitutively active ATF2. Indeed, expression of
transcriptionally inactive ATF2 or peptides that attenuate endog-
enous ATF2 activity inhibits melanoma development and progres-
sion in xenograft models [22–26]. These studies suggest that ATF2
is required for melanoma development and progression.
The transcription factor MITF has been shown to play a central
role in melanocyte biology and in melanoma progression [27,28].
Yet, the role of MITF in early stages of melanoma development
remains largely unexplored. Factors controlling MITF transcrip-
tion have been well documented and include transcriptional
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binding factor 1 (LEF1, also known as TCF), onecut domain 2
(ONECUT-2) and MITF itself [29–33], as well as factors that
repress MITF transcription, including BRN2 and FOXD3
[34,35]. In addition, MITF is subject to several post translational
modifications which affect its availability and activity, including
acetylation, sumoylation and ubiquitination [27,28].
To directly assess the importance of ATF2 in melanoma
development, we employed a mouse melanoma model in which
ATF2 is selectively inactivated in melanocytes. We demonstrate
that melanoma development is markedly attenuated in mice
expressing a transcriptionally inactive form of ATF2 in melano-
cytes. Surprisingly, ATF2 control of melanoma development was
mediated, in part, through its negative regulation of SOX10 and
consequently of MITF transcription. Inhibition of ATF2 abolished
mutant BRAF-expressing melanocytes’ ability to form foci on soft
agar, which was partially rescued when expression of MITF was
attenuated. The significance of these findings is underscored by
our observation of human melanoma tumors, in which high ratio
of nuclear ATF2 to MITF expression was associated with poor
prognosis. These findings identify a novel mechanism underlying
melanocyte transformation and melanoma development.
Results
Generation of melanocyte-specific ATF2 mutant mice
Global Atf2 knockout in mice leads to early post-natal death
[36]. Therefore, the Cre-loxP system was utilized to disrupt Atf2 in
melanocytes. Deletion of its DNA binding domain and a portion of
the leucine zipper motif results in a transcriptionally inactive form
of ATF2 (Figure 1a; [36]). To generate loss-of-function mutants,
we established mice that would allow CRE-dependent deletion of
these domains. Mice homozygous for the loxP-flanked (floxed) Atf2
gene (Atf2
f/f) were born at the expected Mendelian ratios and
presented no apparent abnormalities. In addition, in several tissues
analyzed, ATF2 expression levels were comparable between WT
and Atf2
f/f mice (data not shown).
To elucidate the role of ATF2 in melanoma, Atf2
f/f mice were
crossed with mice harboring a 4-hydroxytamoxifen (OHT)-
inducible Cre recombinase-estrogen receptor fusion transgene
under the control of the melanocyte-specific tyrosinase promoter,
designated Tyr::Cre
ER(T2). Upon administration of OHT, we
predicted that CRE-mediated recombination would be induced in
a spatially and temporally controlled manner in embryonic
melanoblasts, melanocytes, and in putative melanocyte stem cells
[37]. The resulting Atf2
f/f/Tyr-Cre
ER(T2) mice, designated mela-
nocyte-deleted (md) Atf2
md), indeed expressed the gene encoding
the ATF2 transcriptional mutant in melanocytes. Immunoblot
analysis of ATF2 protein confirmed that melanocytes prepared
from wild-type TyrCre
+::Atf2
+/+::Nras
+::Ink4a
2/2 (WT) mice
express a 70 kDa band corresponding to full length ATF2,
whereas melanocytes of TyrCre
+::Atf2
md::Nras
+::Ink4a
2/2 mice
express only a 55 kDa band, corresponding to the size of ATF2
lacking the DNA binding and leucine zipper domains (Figure 1b).
Disruption of ATF2 in melanocytes inhibits melanoma
formation
To address the role of ATF2 in de novo melanoma formation
Tyr::Cre
ER::Nras
Q61K::Ink4a
2/2 (KO of exon 2–3 of Cdkn2a locus,
which encodes for both p16
Ink4a and p19
Arf; [38]) mice, which
develop spontaneous melanoma (Lynda Chin, unpublished obser-
vations), were crossed with Atf2
md mice. Similar to findings reported
by Ackermann et al. [39], mutant N-Ras/Ink4a
2/2 mice developed
melanoma within 8–12 weeks with metastatic lesions often seen in
thelymphnodes.However,theincidenceofmelanomawas lowerin
Tyr::Cre
ER::Nras
Q61K::Ink4a
2/2 mice used in the present study (50%
penetrance, of which 50% of the tumors were confirmed to be
melanoma), probably because expression of mutant NRAS was
induced only after birth, as opposed to activation of NRAS during
embryogenesis, as reported in [39]). Thus, Atf2
md::N-Ras
Q61K::
Ink4a
2/2 mice were used to assess changes in melanoma incidence
in the absence of functional ATF2 over a period of up to 8 months.
In all cases, mouse skin was treated with Tamoxifen within 3–5 days
after birth to inactivate ATF2 (Figure 1b) and with doxycycline in
their drinking water to induce expression of the NRAS mutant
transgene (See Materials and Methods for details; Figure 1c). In the
control group (Tyr::Cre
ER::Atf2
+/+::Nras
Q61K::Ink4a
2/2), 11/21 mice
(52%) developed tumors within 8–16 weeks (Table 1). In ATF2
heterozygotes (Tyr::Cre
ER::Atf2
2/+::Nras
Q61K::Ink4a
2/2), 18/44 mice
(41%) developed tumors within 8–16 weeks, and in the Tyr::Cre
ER::
Atf2
md::Nras
Q61K::Ink4a
2/2 group only 3 of 21 animals (15%)
developed tumors within 24–36 weeks (Figure 1d and Table 1).
To evaluate tumor type, we examined melanoma markers including
DCT and S100 in all tumors (Figure 1e, Figure S1). This analysis
identified 55–63% of tumors as melanomas in both the Atf2
+/+ (7/
11) and Atf2
+/2 (10/18) groups (Table 2). Only one of the three
tumors observed in the Atf2
md group was identified as a melanoma.
Kaplan Meier curve did not reveal significant differences in survival
among the different genotypes, probably since this study was
primarily designed to follow tumor incidence. Common to all
genotypes, most tumors that were not identified as melanomas were
fibrosarcomas and lymphomas, consistent with previous reports
[38]. These data suggest that transcriptionally active ATF2 is
required for melanoma development in the Nras
Q61K::Ink4a
2/2
mouse melanoma model.
Identification of MITF as an ATF2-regulated gene
To assess the mechanism underlying ATF2’s contribution to
melanoma development, we conducted gene profiling array
Author Summary
Understanding mechanisms underlying early stages in
melanoma development is of major interest and impor-
tance. Recent studies indicate a role for MITF, a master
regulator of melanocyte development and biogenesis, in
melanoma progression. Here we demonstrate that the
transcription factor ATF2 negatively regulates MITF tran-
scription in melanocytes and in about 50% of melanoma
cell lines. Increased MITF expression, seen upon inhibition
of ATF2, effectively attenuated the ability of BRAF
V600E-
expressing melanocytes to exhibit a transformed pheno-
type, an effect partially rescued when MITF expression was
also blocked. Significantly, the development of melanoma
in mice carrying genetic changes seen in human tumors
was inhibited upon inactivation of ATF2 in melanocytes.
Melanocytes from mice lacking active ATF2 expressed
increased levels of MITF, confirming that ATF2 negatively
regulates MITF and implicating this newly discovered
regulatory link in melanoma development. Primary mela-
noma specimens that exhibit a high nuclear ATF2-to-MITF
ratio were found to be associated with metastatic disease
and poor prognosis, further substantiating the significance
of MITF control by ATF2. In all, these findings provide
genetic evidence for the role of ATF2 in melanoma
development and indicate an ATF2 function in fine-tuning
MITF expression, which is central to understanding MITF
control at the early phases of melanocyte transformation.
ATF2 Regulates MITF and Melanoma Development
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+::Atf2
+/+::
Nras
Q61K::Ink4a
2/2 and Tyr::Cre
+::Atf2
md::Nras
Q61K::Ink4a
2/2 mice.
Analysis was limited to melanocytes, since, as reported above, only
one melanoma formed in the ATF2 mutant group. In all cases,
ATF2 was inactivated and NRAS was induced in culture within
48h of plating cells, as monitored by western blots (Figure 1b, 1c
and data not shown). Melanocytes were enriched, and immuno-
staining with appropriate markers confirmed that samples were
free of keratinocytes and fibroblasts (data not shown; see Materials
and Methods for details). RNA was prepared from cultures and
two biological and technical replicates were used for data analysis.
As shown in Table 3, among transcripts differentially expressed in
ATF2 WT and mutant cultures were several factors that play an
important role in melanocyte pigmentation, including Mitf, Silver,
Tyrp1 and Dct. qPCR analysis, performed on independently
prepared RNA samples from melanocytes expressing WT
(Tyr::Cre
+::Atf2
+/+::Nras
Q61K::Ink4a
2/2) or mutant ATF2 (Tyr::
Cre
+::Atf2
md::Nras
Q61K::Ink4a
2/2), confirmed altered expression of
pigmentation genes (Table 3). These data provide the initial
indication that ATF2 negatively regulates Mitf and several other
important pigmentation genes. As the pigmentation genes
identified in this array are known to be regulated by MITF [27],
we focused on regulation of MITF by ATF2.
MITF is negatively regulated by ATF2 in mouse and
human melanocytes
To confirm that ATF2 negatively regulates Mitf expression, we
assessed MITF transcription in primary mouse melanocytes
harboring WT (Tyr::Cre
2::Atf2
+/+) or mutant (Tyr::Cre
+::Atf2
md)
forms of ATF2. RNA prepared from whole skin of these mice (3
mice per group) was subjected qPCR analysis. Significantly, Mitf
expression was inversely correlated to the presence of functional
ATF2; samples obtained from ATF2 mutant skin exhibited a
greater than 2-fold increase in MITF expression compared with
those obtained from WT ATF2 mice (Figure 2a). Likewise, we
found that genes transcriptionally regulated by MITF, such as Dct,
Silver and Tyrp1, were upregulated in the skin of mutant ATF2
mice (Figure 2a). The degree of altered expression of pigmentation
genes was less pronounced in whole skin samples than in cultured
melanocytes (Table 3), probably due to confounding effects of in
vitro cell culture. To confirm the qPCR data, we performed
immunostaining of skin tissue samples obtained from 4 days old
WT or ATF2 mutant mice and observed increased MITF
expression in melanocytes from Atf2
md mice relative to their WT
counterparts (Figure 2b). Quantification of MITF staining
revealed an approximate 2-fold increase in nuclear MITF
expression in Atf2
md compared to WT mice (Figure 2c). Of note,
the level of S100 staining in the hair matrix was markedly reduced
in the skin of Atf2
md mice. At a later time point (2 weeks)
representing an advanced stage of melanocyte development, S100
staining was similar in both genotypes, while MITF expression
remained upregulated in Atf2
md mice (not shown). In all, these data
confirm our initial observations in primary mouse melanocytes
that MITF levels are elevated in ATF2 mutant-expressing cells.
Additional assessment was performed in melan-Ink4a-Arf1 mela-
nocytes, a line derived from black Ink4a-Arf null mice [40], and in
primary human melanocytes. In both, ATF2 expression was
inhibited by viral infection with the corresponding mouse or human
shRNA (shATF2). Infection of either primary human (Figure 3a) or
melan-Ink4a-Arf1 melanocytes (Figure 3b) with shATF2 markedly
increased MITF transcription and protein expression (Figure 3a,
3b). These findings show that loss of transcriptionally active ATF2
allows higher expression of MITF and strongly suggest that ATF2
negatively regulates MITF expression in melanocytes.
MITF transcription is negatively regulated by ATF2 in
about 50% of human melanoma cells
Given that ATF2 negatively regulates MITF in melanocytes of
mouse and human tissues and in related melanocyte cell lines, we
asked whether ATF2 also regulates MITF in human melanoma cells.
Initially, we assessed changes in MITF expression in six human
Table 1. Tumor incidence in mixed genetic backgrounds.
Genotype No of mice Tumor Incidence
ATF2
+/+TyrCre
+Nras
+Ink4a
2/2 21 11/21 (52%)
ATF2
+/2TyrCre
+Nras
+Ink4a
2/2 44 18/44 (41%)
ATF2
2/2TyrCre
+Nras
+Ink4a
2/2 21 3/21 (15%)
Shown is the tumor incidence in the different genotypes.
doi:10.1371/journal.pgen.1001258.t001
Table 2. Tumors positive for melanoma markers S100 and
DCT.
Genotype Melanomas Non melanomas
ATF2
+/+TyrCre
+Nras
+Ink4a
2/2 7/21 (33%) 4/21 (19%)
ATF2
+/2TyrCre
+Nras
+Ink4a
2/2 10/44 (22%) 8/44 (18%)
ATF2
2/2TyrCre
+Nras
+Ink4a
2/2 1/21 (5%) 2/21 (10%)
In order to distinguish melanoma from non-melanoma tumors were subjected
to staining with S100 and DCT (see Figure 1E, Figure S1). Only those stained
positive for both markers were considered as melanomas. Number of positive
stained out of total melanomas is shown (percent positive) for each of the
genotypes. Statistical analysis using Chi-square assay revealed that the
differences between # of melanomas between the ATF2
2/2 and ATF2
+/+
genotypes are significant (p=0.018). Differences among the other groups were
not significant (differences between # of melanomas between the ATF2
2/+ and
ATF2
+/+ p=0.36; differences between # of non-melanomas between the
ATF2
2/2 and ATF2
+/+ groups p=0.37. differences between # of non-
melanomas between the ATF2
2/2 and ATF2
2/+ p=0.92).
doi:10.1371/journal.pgen.1001258.t002
Figure 1. Melanoma development is inhibited in Nras/Ink4a mice expressing a melanocyte-specific ATF2 mutation. A. Targeting
strategy shows wild-type allele of Atf2 encompassing exons 8 and 9 (boxes) and flanking loxP sequences (arrowheads). B. Expression of ATF2 assessed
by immunoblot in melanocytes derived from TyrCre
+::Atf2
+/+::Nras
Q61K::Ink4a
2/2 and TyrCre
+::Atf2
md::Nras
Q61K::Ink4a
2/2 mice and treated with 4-OHT,
enabling expression of a mutant lacking the DNA binding and leucine zipper domains. b-actin served as a loading control. C. Induction of mutant
NRAS in melanocytes. Shown is RT-PCR analysis (20 cycles) of NRAS
Q61K transcript levels in melanocyte cultures treated with doxycycline (2mg/ml).
RNA from untreated melanocytes served as a control (right lane), and Cyclophilin A served as an internal control. D. Melanoma development is
inhibited in TyrCre
+::Atf2
md::Nras
Q61K::Ink4a
2/2 mice. Image represents animals of TyrCre
+::Atf2
+/+::Nras
Q61K::Ink4a
2/2 or TyrCre
+::Atf2
md::Nras
Q61-
K::Ink4a
2/2 genotype that were analyzed for tumor formation within 8–32 weeks. E. Representative staining of melanoma tumors from mice of the
TyrCre
+::Atf2
+/+Nras
Q61KInk4a
2/2genotype for melanoma markers. Immunohistochemistry was performed on 5 mM paraffin-embedded samples.
Sections were incubated with S-100 and DCT antibody (Ab) or control secondary antibody (Cont) and counterstained with hematoxylin. Scale
bar=50 micron. Slides were scanned by scanscope at 206(IHC) and 406(H&E).
doi:10.1371/journal.pgen.1001258.g001
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and in which ATF2 expression was effectively inhibited by
corresponding shRNA (shATF2). In all cases, shRNA specificity
was confirmed using three independent sequences (data not shown).
Surprisingly, the six melanoma lines fell into two classes based on
distinct patterns of regulation of MITF by ATF2 (Table 4). The first
class comprised four of the six melanoma cultures (1205Lu, WM35,
WM793 and WM1361), in which MITF expression was elevated 3–
6-fold following inhibition of ATF2 expression (Figure 3c, S2a).
Conversely, a second class of cells, including MeWo and 501Mel
cells, exhibited decreased MITF expression after ATF2 knockdown
(KD), suggesting positive regulation of MITF by ATF2 (Figure 3d,
S2b). Notably, this latter group showed high levels of basal MITF
expression [41,42], suggesting that regulation of MITF expression in
these cells differs mechanistically from that of the first group. Further,
in response to stress (UV or hypoxia) the MeWo and 501Mel lines
further reduced MITF expression (Figure 3d and data not shown),
providing further evidence for differential regulation of MITF in
these cells both prior to and in response to stress stimuli. Additional
analyses were performed, employing 12 more melanoma cell lines.
Inhibition of ATF2 expression revealed that 4/12 exhibited increase
in MITF expression, while6/12 decreased MITF expression. Two of
the 12 lines did not exhibit change in MITF expression following
ATF2 KD (Table 4, S5). Collectively, out of 18 melanoma lines we
found that 8 (44%) retained similar negative regulation of MITF by
ATF2 as observed in the melanocytes. However, another 8 (44%)
exhibited positive regulation of MITF by ATF2, pointing to a
transcriptional switch that occurred in the course of melanocyte
transformation. MITF was not affected by altered ATF2 expression
in 2/18 cell lines (Table 4, Figure S5). In all, in about 50% of the
melanomacelllinesATF2elicitsnegativeregulationofMITF,similar
to what was seen in human and mouse melanocytes.
ATF2 regulation of MITF is mediated by discrete
promoter elements
MITF transcription isregulated bycomplex positiveand negative
cues [27]. Forinstance, whileCREB and SOX10 positivelyregulate
MITF, BRN2 and FOXD3 have been shown to downregulate
MITF expression [29,30,34,35]. Hence we used melanocytes and
representative melanoma lines to assess mechanisms underlying
positive or negative regulation of MITF. Infection of the human
melanocyte line Hermes 3A with shATF2 effectively inhibited ATF2
expression, upregulated Mitf transcription and increased transcrip-
tion of SOX10 and FOXD3 (from 7- to 10-fold) and to a lesser
extent of Pax3 and Brn2 (from 1.5- to 2-fold) (Figure 4a, S3a).
Similarly, inhibition of ATF2 transcription in human melanoma
1361 cells increased SOX10 and FOXD3 transcription, albeit, to a
lesser degree (3- and 1.5-fold, respectively) compared with human
melanocytes (Figure S3b). Neither BRN2 nor PAX3 transcription
was elevated in melanoma cells in which ATF2 expression was
inhibited (Figure S3a). These observations suggest a role for ATF2
in FOXD3- and SOX10-mediated regulation of MITF transcrip-
tion in melanocytes and melanoma cells.
To assess the possible role of FOXD3 in regulation of MITF we
inhibited FOXD3 expression in melanocytes expressing control
shRNA and shATF2. Inhibition of FOXD3 expression increased
SOX10 transcription and protein expression, albeit to lower levels
compared with inhibition of ATF2 expression (Figure S4).
Concomitant increase of MITF RNA and protein levels was also
lower, compared with that seen upon inhibition of ATF2
expression. Notably, inhibition of both ATF2 and FOXD3
resulted in additive increase of SOX10 and MITF (Figure S4).
These data suggest that FOXD3 may also contribute to negative
regulation of MITF in melanocytes, independent of ATF2. Since
inhibition of FOXD3 elicited a less pronounced effect compared
with ATF2, and since the effect appeared ATF2-independent and
furthermore did not appear to mediate similar changes in human
melanoma cells (Figure S3b and data not shown), we focused on
assessment of direct mechanisms underlying ATF2 effect on MITF
transcription.
To this end we first analyzed MITF promoter sequences for
ATF2/CRE elements (Cyclic AMP response element), which can
be targeted by ATF2, as well as sequences recognized by BRN2
and SOX10 using a luciferase reporter construct (MITF-Luc) [43].
Using either a wild-type (WT) construct or one in which the BRN2
site was mutated, we observed increased luciferase activity
following inhibition of ATF2 transcription in WM1361 melanoma
(Figure 4b), as well as in LU1205 and WM35 melanoma cells (data
not shown). The relative increase in luciferase activity following
ATF2 inhibition was equivalent in both constructs, suggesting that
an ATF2 effect is not mediated by BRN2 (Figure 4b, left panel).
Similarly, MITF transcriptional activities were altered to a similar
degree following inactivation of the CRE element (Figure 4b, right
panel), suggesting that ATF2 down-regulation of the MITF
promoter is indirect. We therefore assessed whether SOX10,
which positively regulates MITF and whose transcription
markedly increases in melanocytes and melanoma cells in which
ATF2 expression is inhibited (Figure 4a, S3b), may mediate ATF2
effect on MITF transcription. Analysis of a MITF-Luc construct
harboring a mutant SOX10 binding site revealed that ATF2
inhibition no longer elicited increased MITF transcription in
human melanocytes or in melanoma cells (Figure 4c). In
agreement, inhibition of SOX10 expression by corresponding
siRNA attenuated the increase in MITF transcription seen in
shATF2-expressing human melanocytes (Figure 4d) or melanoma
cells (Figure 4e). These results suggest that ATF2 regulation of
MITF transcription is mediated by SOX10. In agreement,
chromatin immunoprecipitation (ChIP) assays confirmed in-
creased binding of SOX10 to the MITF promoter in melanoma
cells expressing shATF2 (Figure 5a).
A putative response element for AP1 (which can serve as an
ATF2 response element through ATF2 heterodimerization with
Table 3. Microarray analysis of ATF2
+/+TyrCre
+Nras
+Ink4a
2/2
and ATF2
2/2TyrCre
+Nras
+Ink4a
2/2melanocytes and
confirmation by qPCR.
Gene name Microarray (ATF2
2/2/WT) qPCR confirmation
Cyclin D1 0.4 0.425
ESAM1 0.09 0.123
Angiopoietin 2 0.254 0.129
KIflc 0.419 0.56
MITF 7.3 1.91
PCDH7 0.46 0.225
Silver 45.27 74.88
DCT 9.0 18.9
Tyrp1 2.3 12.7
Tgfbi 0.34 0.49
Primary melanocytes were isolated and inactivation of ATF2+ induction of N-
Ras expression was performed in culture (see Materials and Methods for details).
RNA prepared from the cells was used for array analysis. Data shown represents
2 biological and 2 technical replicates for the array studies and 3 replicates for
the qPCR analyses (see Materials and Methods for details).
doi:10.1371/journal.pgen.1001258.t003
ATF2 Regulates MITF and Melanoma Development
PLoS Genetics | www.plosgenetics.org 5 December 2010 | Volume 6 | Issue 12 | e1001258Figure 2. ATF2 negatively regulates MITF in melanocytes. A. qPCR performed on RNA prepared from skin of 4-day-old ATF2 WT or Atf2
md
mice (3 mice per sample; see Materials and Methods for details). Shown is representative analysis of 3 independent samples. B. IHC analysis of mouse
skin prepared from 4-day-old mice. Staining with corresponding antibodies was performed as indicated in Experimental Procedures. Magnifications
ATF2 Regulates MITF and Melanoma Development
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of the Sox10 promoter [44]. We examined potential ATF2
binding to this element by ChIP and found that endogenous
ATF2, but not ATFa, binds to that AP1 sequence (24797–4791)
in both human melanocytes and melanoma cells (Figure 5b). We
next set to identify ATF2 heterodimeric partner, which could
mediate negative regulation of SOX10 transcription. Among
members of the JUN family implicated in transcriptional silencing
is JunB. Thus, further assessment was performed to determine if
JunB functions as an ATF2 heterodimerization partner to regulate
SOX10 transcription through the AP1 site. ChIP analysis
confirmed that JunB binds to the AP1 site found in SOX10
promoter sequences (Figure 5c). To confirm a possible role for
JunB in regulating MITF transcription we asked whether
expression of TAM67, a negative regulator of Jun family
members, could attenuate the binding and transcriptional
activities elicited by JunB. Expression of TAM67 indeed reduced
the degree of ATF2 and JunB binding to the AP1 site on SOX10
promoter. Further, KD of ATF2 expression abolished binding of
both ATF2 and JunB to the AP1 site on the SOX10 promoter
(Figure 5c). These data confirm the presence of ATF2-JunB
complex on Sox10 promoter and suggest that ATF2 recruits JunB
for binding to the AP1 site on SOX10 promoter. To assess the role
of JunB on SOX10 transcription we have monitored changes in
Sox10 expression at the protein and RNA levels. Expression of
TAM67 caused increased expression of SOX10 in both human
melanoma (,2 folds; Figure 5d) and melanocytes (,3 folds;
Figure 5e), indicating some relief of JunB inhibition. Co-expression
of TAM67 with Jun B attenuated this increase, reducing the level
of Sox10 expression to basal levels (Figure 5d, 5e). Over-expression
of JunB, but not Jun D, effectively inhibited Sox10 expression in
both the melanoma and melanocytes cells (Figure 5d, 5e). These
data suggest that JunB mediates inhibition of Sox10 expression.
To further reveal the role of ATF2 in this inhibition, we assessed
the effect of JunB on Sox10 expression in cells expressing control
shRNA or shATF2. While ectopic expression of JunB reduced the
expression of Sox10 in control shRNA-expressing cells, such
decrease was no longer seen in cells expressing shATF2 (Figure 5f).
Collectively, these findings suggest that ATF2, in concert with
JunB, is responsible for inhibition of Sox10 expression.
We next assessed the effect of ATF2 on SOX10 and MITF
expression in 12 additional human melanoma cell lines. In all cases
cells were infected with shATF2 and changes in SOX10 and
MITF were monitored at the level of RNA. Notably, about 4/12
melanoma lines revealed increase in both SOX10 and MITF
expression upon KD of ATF2 (Figure S5, Table 4). In contrast, 6/
12 melanoma lines revealed decrease in MITF expression, of
which 5 also shown decrease in SOX10 expression, pointing to
positive regulation of SOX10 and MITF in these melanoma cells.
In two out of the 12 melanoma lines ATF2 affected SOX10 but
not MITF transcription (Figure S5). Overall, our cohort of 18
melanoma lines revealed that about 50% of the melanomas
retained negative regulation of MITF by ATF2, as seen in the
melanocytes (primary and cell lines) (Table 4).
To further assess whether ATF2 regulation of MITF is SOX10-
dependent in melanocytes and melanoma cells, we coexpressed
SOX10 in shATF2-expressing cells. As seen in earlier analysis,
inhibition of ATF2 expression caused increase in MITF transcription
in the human melanocytes and 4 melanoma cell lines, (WM1361,
WM793, LU1205, WM35; Figure S6). Notably, the melanocytes and
2/4 melanoma cell lines revealed ATF2 effect on MITF expression is
SOX10-dependent (WM1361, WM793; Figure S6). Two of the four
melanoma cell lines did not reveal increased SOX10 expression,
although they retained increased MITF expression, upon inhibition
of ATF2 (Lu1205, WM35; Figure S6). These findings confirm that
while in melanocytes, expression of SOX10 and MITF is negatively
regulated by ATF2, this mechanism is conserved in approximately
half of melanomas surveyed.
Along these lines, the two melanoma lines (MeWo and 501 Mel)
that exhibit positive regulation of MITF by ATF2 also exhibited
positive regulation of SOX10 by ATF2 (Figure S7). Inhibition of
ATF2 expression reduced SOX10 and MITF RNA and protein
levels (Figure S7a–c). In order to determine whether JunB lost its
ability to elicit negative regulation of SOX10 and MITF in
melanoma cells where ATF2 no longer inhibited SOX10 or MITF
expression, we transfected those cell lines with TAM67 and JunB
alone and in combination. In these cells, whereas TAM67
effectively attenuated Sox10 and MITF expression, JunB did not
alter expression of these genes, suggesting that positive regulation
of MITF and SOX10 by ATF2 depends on other members of the
Jun family of transcription factors (Figure S7d). Conversely,
TAM67 or JunB had no effect on melanoma cells in which ATF2
inhibits MITF independently of SOX10, suggesting that in these
cases, ATF2 likely cooperates with transcription factors other than
JunB to elicit negative regulation of SOX10 and MITF (Figure
S7d). Consistent with this observation, ChIP assay confirmed
ATF2 and CREB, but not JunB, binding to the Sox10 promoter in
these cells (Figure S7e). These findings suggest that changes in
ATF2 heterodimeric partner (from JunB to CREB) are likely to
cause the switch from negative to positive regulation of SOX10,
and in turn, MITF (see below). The possibility that altered
expression of JunB may account for ATF2 positive or negative
regulation of Sox10 and MITF were excluded, as no clear
correlation between JunB expression and the ability of ATF2 to
elicit negative regulation of Sox10/MITF were seen (Figure S7f).
Among response elements potentially required to upregulate
MITF transcription is the CRE element, which is implicated in
CREB-mediated upregulation of MITF transcription [45].
Although transcriptional activity from a CRE mutant MITF
promoter was lower compared to the WT promoter (30%), it was
no longer responsive to inhibition of ATF2 expression in the
MeWo cells (Figure S8a). Pull-down assays using biotin-tagged
MITF promoter sequences harboring the CRE identified ATF2
and CREB as CRE-bound proteins in MeWo melanoma cells
(Figure S8b). In agreement, ChIP analysis confirmed occupancy of
the CRE site on MITF promoter by ATF2 (Figure S8c). These
findings are consistent with the fact that ATF2 heterodimerizes
with CREB [9] and with a report that p38/MAPK14 (which
phosphorylates ATF2) plays an important role in MITF
transcription dependent on the CRE site [46]. These results
establish that ATF2-dependent activation of MITF transcription
in these melanoma cells is mediated through the CRE site, likely in
cooperation with CREB. Notably, MeWo and 501Mel lines are
known to express high MITF levels compared to other melanoma
lines [41,42], suggesting these cells harbor distinct mechanisms
that preclude negative regulation of MITF by ATF2.
shown are 20 and 406. S100 staining reveals changes in the hair matrix (low magnification) and migrating melanoblasts (higher magnification) Scale
bar=100 micron. C. Quantification of immunostaining was performed using the automated Aperio ScanScope CS system (see Materials and Methods
for details). The percentage (%) reflects the amount of positive signal in five selected fields representing longitudinal sections through the skin and
containing the entire length of hairs, from the bulb with the subcutis to the epidermis.
doi:10.1371/journal.pgen.1001258.g002
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PLoS Genetics | www.plosgenetics.org 7 December 2010 | Volume 6 | Issue 12 | e1001258Figure 3. ATF2 regulates MITF in melanocytes and melanoma cells. A. Upper panel, ATF2 was knocked down in primary human melanocytes
(one 10 cm plate each, 50% confluent) and cells were either untreated or kept under hypoxia (1%) for 16h. Cells were lysed and Western blotting was
carried out with the indicated antibodies. Lower panel, RNA was extracted from the above samples and qPCR was carried out using MITF primers.
Cyclophilin A was served as an internal control. B. Upper panel, ATF2 was knocked down in melan-Ink4a-Arf1 mouse melanocytes and Western
blotting was performed using the indicated antibodies. Lower panel, qPCR of the above samples was carried out using MITF primers. C. Left panel,
Lu1205 melanoma cells (one 10 cm plate each, 50% confluent) were transduced with either empty or shATF2 lentiviral vectors. Cells were left
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soft agar in shATF2-expressing melanocytes
To determine whether the contribution of ATF2 to melanocyte
transformation and development is MITF-dependent, we assessed
melanocytes’ ability to grow and form colonies in soft agar, which
is indicative of their transformed potential. Expression of mutant
BRAF
V600E in immortal melanocytes is reportedly sufficient for
growth on soft agar [47]. Thus we infected melan-Ink4a-Arf1
melanocytes with mutant BRAF (Figure 6a) and confirmed their
ability to form colonies in soft agar. Mutant BRAF expression
effectively caused formation of about 1000 colonies per 5000 cells
(Figure 6b, 6c). In contrast, melanocytes infected with BRAF
600E
and with shATF2 formed on average about 20 colonies, indicative
of loss of tumorigenicity (Figure 6b, 6c, 6d) and consistent with our
initial observation that the number of melanoma tumors
significantly decreases in the absence of transcriptionally function-
al ATF2 (Tables 1–2). To determine the importance of MITF at
this early stage of melanocyte transformation we inhibited MITF
expression (using shRNA) in melanocytes expressing mutant
BRAF alone or mutant BRAF+shATF2. Significantly, inhibition
of MITF expression decreased the number of BRAF-induced foci
(from 1000 to about 100 per well). Over-expression of MITF in
BRAF-expressing melanocytes also inhibited focus formation, to a
degree similar to that seen following inhibition of MITF expression
(Figure 6b, 6c, 6d). This observation implies that effective
inhibition or overexpression of MITF attenuates melanocyte
transformation, consistent with previous reports (52). Remarkably,
inhibition of MITF expression in melanocytes expressing both
mutant BRAF and shATF2 rescued, at least partially, melano-
cytes’ ability to form foci on soft agar (400 compared with 20 seen
in shATF2 cells; Figure 6b, 6c, 6d). These findings suggest that
inhibition of MITF expression in melanocytes lacking ATF2
expression can promote transformation. That MITF inhibition in
melanocytes expressing ATF2 WT can attenuate their ability to
form foci on soft agar is attributable to the relative expression of
MITF RNA and protein in each condition (Figure 6d). MITF
expression levels in ATF2 KD cells increased 7.5-fold compared
with control BRAF-expressing melanocytes. Inhibition of MITF
expression in ATF2 KD melanocytes reduced MITF expression
2.5-fold relative to controls, whereas MITF KD alone resulted in
lower MITF expression (5-fold; Figure 6d). Thus, complete
abrogation of MITF expression attenuates melanocyte transfor-
mation, whereas low to moderate levels of MITF expression are
sufficient to promote growth on soft agar. Higher MITF
expression levels, as seen in ATF2 KD cells, result in a total loss
of melanocytes’ ability to form foci on soft agar. These findings are
untreated, kept under hypoxia (1%), or treated with UV-B (21 mJ/cm
2 for 6 h) irradiation. Proteins were prepared 6h after UV-B treatment or 16h after
growth under hypoxia. Proteins were immunoblotted using the indicated antibodies. Right panel, RNA was extracted from cells maintained under the
same conditions, and qPCR was performed using MITF primers. Cyclophilin A was served as an internal control for qPCR. D. The experiment was
carried out in MeWo melanoma cells as described in panel C.
doi:10.1371/journal.pgen.1001258.g003
Table 4. MITF and SOX10 mRNA levels in melanocytes and melanoma cell lines following ATF2 KD.
Melanocytes/Melanoma cells Relative change in MITF mRNA upon ATF2 KD* Level of SOX10 upon ATF2 KD**
Hermes 3A
Melanocytes
6–7 fold increase 6–8 fold increase
Melan-Ink4a-Arf1
Melanocytes
4–6 fold increase ND
Lu1205 2–3 fold increase unchanged
WM35 2.5–3.5 fold increase unchanged
WM1361 4–6 fold increase 3–3.5 fold increase
WM793 1.5–2 fold increase 1.5–2 fold increase
SbCl2 1.5 fold increase 1.5 fold increase
WM4 2 fold increase 2 fold increase
WM9 2 fold increase 1.5 fold increase
WM1650 1.7 fold increase 1.5 fold increase
WM1552 2 fold decrease unchanged
WM3629 2.5 fold decrease 1.7 fold decrease
501MEL 2.5–3 fold decrease 0.6 fold decrease
SK-MEL-2 2.5 fold decrease 2 fold decrease
SK-MEL-5 3 fold decrease 2 fold decrease
SK-MEL-8 2.5 fold decrease 1.5 fold decrease
MeWO 2–2.5 fold decrease 0.5 fold decrease
UACC903 4 fold decrease 1.5 fold decrease
A2068 unchanged 2.5 fold decrease
WM1366 unchanged 2.3 fold increase
*Relative changes in MITF upon ATF2 KD are shown as fold change at RNA level, determined by qPCR. Data shown represent triplicate analyses.
**Relative changes in SOX10 upon ATF2 knock down (KD) are also quantified by qPCR analysis. ND: not determined.
doi:10.1371/journal.pgen.1001258.t004
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of MITF are optimal for growth and melanoma development [48]
and in agreement with our observations in a mouse melanoma
model.
We next assessed whether inhibition of melanocyte growth on
soft agar by altered ATF2 and/or MITF expression can be
attributed to decreased proliferation or increased apoptosis.
Inhibition of ATF2 expression caused notable accumulation of
cells in G2 (60%), with significant cell death induction (22%)
compared to controls (4%), (Figure 6e, 6f). Interestingly, such
altered cell cycle distribution and cell death rate were associated
with a significant increase in MITF protein levels (Figure 6d). In
contrast, inhibition of MITF expression did not significantly
induce cell death (6.5%) but resulted in fewer cells in G2/M-phase
and more cells in G1, compared with inhibition of ATF2 alone.
These observations suggest that MITF inhibition is sufficient to
reduce the rate of cell cycle progression through G2/M phase and
that inhibited growth of BRAF
600E-expressing melanocytes on soft
agar may be attributed to abrogation of distinct cell cycle-
regulatory mechanisms. Combined inhibition of ATF2 and MITF
restored cell cycle distribution to that seen in control melanocytes,
and reduced cell death from 22.4% to 12.9%. Of interest, MITF
overexpression promoted a similar degree of cell death (11.4%)
without altering cell cycle distribution, similar to combined
inhibition of ATF2 and MITF (Figure 6e, 6f). Together, these
observations suggest that simultaneous inhibition of ATF2 and
MITF averts cell cycle abrogation induced when expression of
either of these factors is perturbed individually, further substan-
tiating regulation of MITF by ATF2.
Low nuclear MITF expression in melanoma tumors that
exhibit strong nuclear ATF2 expression is associated with
poor prognosis
The availability of a melanoma TMA, consisting of over 500
melanoma samples and in which expression of both ATF2 and
MITF in the same tumors had been measured enabled us to assess
possible associations between ATF2 and MITF and their
correlation with survival and other clinical and pathological
factors. Our earlier studies revealed that ATF2 subcellular
localization in tumors is significantly correlated with prognosis:
nuclear localization, reflecting constitutively active ATF2, was
associated with metastasizing tumors and poor outcome [7]. Here
we quantitated immunofluorescent staining of TMAs for MITF
and ATF2 by employing our automated, quantitative (AQUA)
method. To normalize ATF2 and MITF levels, expression of each
of the two proteins in individual patients was divided by the
median expression level of the respective protein in all patients,
and the nuclear ATF2/MITF ratio was calculated and log-
transformed. By ANOVA analysis, the ratio was higher in
metastatic than in primary specimens (t value=2.823,
P=0.0051), as shown in Figure 7a. No association was found
between nuclear ATF2/MITF ratio and disease-specific survival
among patients with metastatic melanoma (not shown). Signifi-
cantly, a high nuclear ATF2/MITF ratio in primary melanoma
specimens was associated with decreased 10-year disease-specific
survival (P=0.0014; Figure 7b). On Cox multivariable analysis,
this association with survival was independent of patient age,
Breslow thickness or the presence or absence of ulceration (data
not shown). Nuclear ATF2 alone in primary specimens was
associated with poor survival, but to a lesser degree than the ratio
of nuclear ATF2/MITF (P=0.0118 for ATF2 as a single
discriminator versus P=0.0014 for the ratio of nuclear ATF2/
MITF). Nuclear MITF as a single discriminator was not a
significant predictor of survival (P=0.185), as was reported
previously using immunohistochemistry [49]. These observations
suggest that active (nuclear) ATF2 in melanoma can suppress
MITF expression, and that this phenomenon is associated with
poor prognosis.
Discussion
Identifying mechanisms underlying early phases of melanocyte
transformation and melanoma development is central to under-
standing the etiology of this devastating tumor, as well as for
developing novel treatment approaches. Previous studies indicate
the presence of mutant BRAF in melanocytic lesions, as well as its
effect on pigment gene expression [6,50,51]. The present study
enhances our understanding of early events contributing to
melanoma development. We demonstrate that loss of a transcrip-
tionally active form of ATF2 in melanocytes inhibits melanoma
development in an Nras/Ink4a model. Our quest to understand
mechanisms underlying ATF2 activity in this process led us to
identify an important role for ATF2 regulation of MITF, an
important regulator of melanocyte biogenesis and a factor
implicated in melanoma progression [49]. Surprisingly, ATF2
negatively regulated MITF expression in mouse and human
melanocytes, suggesting that ATF2 transcriptional activities limit
MITF expression. We demonstrate that such negative regulation is
elicited through downregulation of SOX10 by ATF2, in
cooperation with JunB. A putative AP1 response element has
been identified in SOX10 promoter sequences and ChIP analysis
of this domain showed ATF2 and JunB binding. Overexpression
of JunB efficiently suppressed SOX10 expression in an ATF2-
dependent manner and inhibition of Jun transcriptional activities
phenocopied the effect of shATF2, suggesting that negative
regulation of SOX10 by ATF2 is direct, and is mediated in
cooperation with JunB.
Importantly, ATF2-dependent negative regulation of Sox10 and
consequently of MITF seen in melanocytes, but only in about 50%
of the 18 melanoma cell lines studied here. Correspondingly,
JunB, which is required for ATF2-dependent inhibition of Sox10
transcription, is no longer found on the promoter of SOX10 in
melanoma cells (i.e. 501Mel) that exhibit positive regulation by
Figure 4. Negative regulation of MITF by ATF2 is mediated by SOX10. A. ATF2 was knocked down in human melanocytes (Hermes 3A) and
qPCR was carried out using primers for the indicated mRNAs. B. Melanoma cells (WM1361, one 10 cm plate each, 50% confluent) were transduced
with either empty or shATF2 lentiviral particles. Cells were selected for 3 days with puromycin treatment (1.5 mg/ml) and then transfected with either
a WT MITF-luciferase reporter or one with a mutant BRN2 site (0.5 mg) along with b-gal (0.1 mg) as an internal control. b-gal activity was normalized
for every sample and the relative fold change in reporter activity for control and shATF2 cells is shown. Right Panel- Analysis was performed in
WM1361 melanoma cells using a WT or CRE-mutated MITF promoter. C. Analysis was performed as in panel B using human melanocytes H3A (left
panel) or 1361 melanoma cells (right panel) and the WT MITF promoter or a construct in which the SOX10 site was mutated. D. Human melanocytes
(H3A; one 10 cm plate each, 50% confluent) were infected with control shRNA (SiSC) or shATF2. After puromycin selection for 3 days, control shRNA
cells and ATF2 knock down cells (2610
6) were transfected with either scrambled siRNA (SiSC) or siRNA against SOX10. After 72 h, Western analysis
was carried out using 50 mg of proteins and the indicated antibodies. E. The same analysis was performed in human melanoma cells. Right panel, RNA
was extracted from cells and used for qPCR analysis of MITF transcripts.
doi:10.1371/journal.pgen.1001258.g004
ATF2 Regulates MITF and Melanoma Development
PLoS Genetics | www.plosgenetics.org 11 December 2010 | Volume 6 | Issue 12 | e1001258ATF2 Regulates MITF and Melanoma Development
PLoS Genetics | www.plosgenetics.org 12 December 2010 | Volume 6 | Issue 12 | e1001258ATF2. Rather, CREB and ATF2 are found on SOX10 and MITF
promoters, pointing to a switch in ATF2 heterodimeric partners to
enable positive regulation of these genes. Notably, melanoma cell
lines that exhibit positive regulation of SOX10 and MITF by
ATF2, also show high basal levels of MITF expression [41,42],
suggesting that additional genetic or epigenetic changes distinguish
these lines from melanocytes and the other melanoma lines in
which ATF2 elicits negative regulation of MITF.
Notably, ATF2 control of MITF expression affected the ability
of BRAF
600E-expressing melanocytes to exhibit transformed
phenotype in culture, monitored by their ability to grow on soft
agar. Inhibition of ATF2 abolished soft agar growth of BRAF
600E-
expressing melanocytes, which was partially rescued upon KD of
MITF. Interestingly, both the over expression or the KD of MITF
resulted in inhibition of melanocytes ability to grow on soft agar,
substantiating the notion that a fine balance of MITF expression
must be maintained in order to ensure its contribution to cellular
proliferation and transformation. We propose that excessively low
or high MITF levels block melanocyte transformation, whereas
intermediate levels allow transformation to occur. Overall, our
observations demonstrate that ATF2 plays an important role in
fine-tuning those levels and support the rheostat model proposed
for MITF’s role in melanoma development and progression [48].
Of importance, ATF2 and MITF affect the ability of BRAF
600E-
expressing melanocytes to grow on soft agar via distinct
mechanisms. Whereas specific inhibition of ATF2 causes both
accumulation of cells in G2 and induction of cell death, specific
alteration of MITF protein levels—particularly depletion—
significantly affects cell proliferation and inhibit growth on soft
agar by non-lethally slowing cell cycle progression at G2/M.
These observations are consistent with a report from Wellbrock
and Marais [52], who showed that altered MITF expression
inhibits melanocyte proliferation.
Importantly, inhibiting MITF expression in ATF2 KD
melanocytes was sufficient to partially rescue melanocyte growth
on soft agar. While supportive of our finding in the Nras::Ink4a
mouse melanoma model, where expression of transcriptionally
inactive ATF2 inhibits melanoma formation, these observations
provide the foundation for a model in which ATF2 inhibition
causes increased MITF levels and concomitant inhibition of
melanocyte growth, possible induction of cell death and delayed
development. The latter is suggested by IHC analysis of mouse
skin from ATF2
md mice, which shows notably reduced S100
staining indicative of delayed melanocyte development: ATF2 KO
melanocytes appear to represent anagen stage IV, whereas WT
represent anagen stage VI. This delay was seen at the 4- but not
the 14-day time point, suggesting that an ATF2 effect might be
limited to a specific subpopulation or phase of melanocyte
development. The early (4 day) time point is within the time
frame that allows induction of melanoma development by UV-
irradiation of c-Met or H-Ras mutant mice [53]. It is therefore
plausible that timely control of MITF expression by ATF2
determines melanocyte susceptibility to transformation.
Our analysis of genes whose expression is altered by ATF2 KD
in melanocytes identified a cluster of pigmentation genes, many
reportedly regulated by MITF [6,54]. Therefore, changes in
TYRP1, DCT and SILVER expression could be attributed to
altered MITF expression. However, initial analysis points to a
more complex mechanism since (i) the degree of changes in
expression of these genes was often greater than that seen for
MITF and (ii) expression of some pigmentation genes was found to
be independent of MITF in some melanoma and melanocyte
cultures. Hence, further studies are required to address mecha-
nisms underlying ATF2 regulation of these pigmentation genes
and the significance of such regulation to melanocyte transforma-
tion and melanoma development. While our present studies
focused on the ATF2-MITF axis, it is expected that additional
ATF2-regulated genes contribute to melanoma development [12].
In agreement, our earlier studies using both human and mouse
melanoma lines demonstrate that inhibition of ATF2 effectively
inhibits tumorigenesis and blocks metastasis [22–26].
Important for ATF2 function is its subcellular localization.
While findings presented here position ATF2 as an oncogene
functioning in melanocyte transformation and melanoma devel-
opment, earlier studies from our laboratory and others suggest that
in keratinocytes and mammary glands, ATF2 elicits a tumor
suppressor function [55,56]. Of interest, assessing the localization
of ATF2 in the melanoma cell lines studied here revealed that all
express nuclear ATF2. Interestingly, in most cases the nuclear
staining revealed a punctate staining, resembling the localization
of ATF2 to DNA repair foci following DNA damage (Figure S9). A
possible link between the presence of ATF2 in repair foci in most
melanoma cells points to the possible presence of activated DNA
damage response which may be associated with genomic
instability [19,20]—aspects that will be explored in future studies.
Significantly, the appearance of nuclear ATF2 is correlated with
poor prognosis in melanoma, whereas melanomas that exhibit
cytosolic ATF2 exhibit a better survival. Notably, cytosolic ATF2
is primarily seen in non-malignant skin tumors [55]. Here we
demonstrate that high nuclear ATF2/MITF ratios are associated
with poor prognosis in primary melanomas, but not with
metastatic melanomas. The latter finding attests for the important
role ATF2 plays to control MITF expression in the early phase of
melanocyte transformation and melanoma development.
Overall, using the mutant Nras/Ink4a melanoma model we
provide genetic evidence for a central role for ATF2 in melanoma
development. We demonstrate that in the absence of transcrip-
tionally active ATF2, melanoma formation is largely inhibited.
Furthermore, our data point to an unexpected role of ATF2 in
fine-tuning of MITF transcription through regulation of its positive
regulator SOX10. Mouse melanoma models and in vitro
transformation studies indicate that this newly identified regula-
tory pathway is required for early phases of melanocyte
transformation. Given that ATF2 affects activity of the oncogenes
N-Ras (mouse model) and BRAF (melanocyte growth on soft agar);
Figure 5. ATF2 and JunB negatively regulate SOX10 transcription, with concomitant effect on MITF. A. Chromatin immuno-precipitation
were performed using antibodies to SOX10 or CREB (or rabbit IgG as control) in WM1361 melanoma cells expressing either control shRNA or ATF2
shRNA. The MITF promoter sequence spanning 2300 to 2120 (180bp containing SOX10 binding sites and a CRE site) was amplified using MITF-
specific primers. GAPDH served as a control. B. ChIP was performed using the indicated antibodies followed by amplification of the SOX10 promoter
sequence containing AP-1 binding sites (24797 to 24791). GAPDH served as control. C. ChIP analysis was carried out using ATF2 or JunB antibodies
in cells that express either shcontrol, shATF2 or Jun DN construct TAM67. D. Expression of JunB or JunD (3 mg) alone or in combination with TAM67
(2 mg) was performed in WM1361 melanoma cells and expression of SOX10 protein was monitored in westerns and quantified using the LICOR
imaging system. Corresponding changes in level of MITF transcripts were assessed by qPCR (Lower panel). E. Experiment similar to shown in panel D
was performed in the melanocytes H3A cell line. F. The effect of JunB on SOX10 expression was assessed in melanoma WM1361 cells expressing
control or shATF2. The right panel shows the level of MITF transcripts quantified by qPCR.
doi:10.1371/journal.pgen.1001258.g005
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carry either of these mutations.
Materials and Methods
Ethics statement
Research involving human participants has been approved by
the institutional review board at Yale University (where the TMA
was prepared and analyzed). All animal work has been conducted
according to relevant national and international guidelines in
accordance with recommendations of the Weatherall report and
approved by the IACUC committee at SBMRI.
Animal treatment and tumor induction protocols
Mice bearing a conditional allele for mutant ATF2 in which the
DNA binding domain and part of the leucine zipper domain were
deleted, were generated as previously described [36,55]. To study
the function of ATF2 in melanocytes, we utilized the Cre-loxP
system for disruption of the ATF2 gene in melanocytes [37]. The
Tyr::Cre
ER::Atf2
md mice and their littermate controls (WT) were of
FVB/129P2/OlaHsd (TyrCre
ERT mice were FVB, ATF2
fl/fl were
129P2/OlaHsd) and N-Ras/Ink4a
2/2 mice were C57Bl/6/
129SvJ. For melanoma studies we have used Tyr::Cre
ER::Nras
Q61K::
Ink4a
2/2 mice (developed at HMS by LC) following their cross
with the Tyr::Cre
ER::Atf2
md mice.
Immunohistochemistry
Skin specimens were fixed in neutral buffered formalin solution
and processed for paraffin embedding. Skin sections (5 mmi n
thickness) were prepared and deparaffinized using xylene. For
MITF, DCT and S100 immunostaining, tissue sections were
incubated in DAKO antigen retrieval solution, for 20 min in a
boiling bath, followed by treatment with 3% hydrogen peroxide for
20 min. Antibodies against MITF (1:100 from Sigma), DCT (1:500,
kind gift from Dr. Vincent Hearing) and S100 (1:100, DAKOCy-
tomation; Carpinteria, CA) were allowed to react with tissue
sections at 4uC overnight. Biotinylated anti-rabbit IgG was allowed
to react for 30 min at room temperature and diaminobenzidineor
Nova Red were used for the color reaction. Hematoxylin was used
for counterstaining. The control sections were treated with normal
mouse serum or normal rabbit serum instead of each antibody.
Cell culture
Immortalized human melanocytes Hermes 3A which has hTERT
(puro) and CDK4 (neo) expression [57] were grown in RPMI 1640
medium containing Fetal Bovine Serum (FBS, 10%), 12-O-
tetradecanoyl-phorbol-13-acetate (TPA, 200 nM, Sigma, St. Louis,
MO), Cholera toxin (200 pM, Sigma), human stem cell factor
(10 ng/ml, R&D systems, Minneapolis, MA), and endothelin 1
(10 nM, Bachem Bioscience Inc., Torrance, CA). Primary human
melanocytes (NEM-LP; Invitrogen) were grown in medium 254 and
HMGS (Cascade Biologics). Mouse melanocytes (melan-Ink4a-Arf1)
were grown as for immortalized human melanocytes excluding
human stem cell factor and endothelin. Melanoma cell lines were
grown in DMEM medium supplemented with 10% FBS and
penicillin/streptomycin (P/S; Cellgro). Melanoma cell lines used in
this study LU1205, WM793, 501MEL, WM35, WM1361, MeWO
(kind gift from Meenhard Herlyn), UACC903 were maintained in
DMEM medium supplemented with 10% FBS and Penicillin/
Streptomycin. Melanoma cell lines SbCl2, WM9, WM4, WM1650,
A2068, WM1366, WM3629, WM1552, SKMEL2, SKMEL5, and
SKMEL8 were maintained in RPMI medium supplemented with
10%FBS and Penicillin/Streptomycin. Primary melanocytes cultures
were prepared from mice carrying the Atf2 WT or mutant genotypes
and N-Ras/Ink4a
2/2as follows. Dorsal-lateral skin was removed from
one day-old pups, disinfected with 70% ethanol for 1 min and then
washed at least twice with sterile PBS. The skin was submerged in 16
Trypsin/EDTA overnight at 4uC and next day, the skin was placed
in a Petri dish with mouse melanocyte culture medium (described
below). The epidermis and sheared tissue was removed and discarded
with forceps. The tissue was transferred to 15 mlcentrifuge tubes and
vortexed vigorouslyuntil solution becomes cloudy (1–2 min).The cell
suspension was transferred to tissue culture flasks. After 3 days,
melanocyte growth medium containing 0.8 mg/ml geneticin (Sigma-
Aldrich) was added to eliminate contaminating fibroblasts (melano-
cytes are resistant to such treatment). Geneticin-containing medium
was removed and replaced with fresh media after 1 day. Media was
changed twice a week. Primary mouse melanocytes were grown in F-
12 media (Invitrogen) containing 20% L-15 media (Invitrogen), 4%
of FBS and Horse serum (Invitrogen), Penicillin (100 units) and
streptomycin (50 mg) antibiotics, db-cAMP (40 mM, Sigma-Aldrich),
12-O-tetradecanoyl-phorbol-13-acetate (TPA, 50 ng/ml, Sigma-
Aldrich), alpha-Melanocyte stimulating hormone (a-MSH, 80 nM,
Sigma-Aldrich), Fungizone (2.5 mg/ml, Sigma-Aldrich) and melano-
cyte growth supplement (Invitrogen). Primary melanocytes were
treated with 4-OHT (10 mM) for 8h followed by addition of
doxycycline (2 mg/ml) for 24h to inactivate ATF2 and induce
expression of N-Ras.
Constructs
ATF2-specific shRNA clones were obtained from Open
Biosystems (catalog no. RHS4533). Five different shRNA were
obtained and tested for their efficiency of KD. Clone
TRCN0000013714 was more efficient in inhibiting ATF2 in
human cell lines while clone TRCN0000013713 was more
efficient for knocking down mouse ATF2. For subsequent
experiments we used the respective shATF2 clone depending on
human or mouse cell lines. We also tested 3 different clones for
KD of ATF2 to rule out any off target effect (Data not shown).
siRNA control (cat # 4611) and three SOX10-specific siRNA
oligonucleotides were obtained from Ambion (cat # 4392420).
Four FOXD3 specific siRNA were obtained from Dharmacon
(Cat # J-009152-06 -07, -08, -09). These siRNAs were pooled
together in equimolar ratio for transient transfection. An MITF
Figure 6. MITF down-regulation partially rescues colony formation by BRAF
V600E-expressing mouse melanocytes with inhibited ATF2
expression. A. Melan-Ink4a-Arf1 cells were stably transduced with wild type BRAF or BRAF
V600E, followed by treatment with ICI 182780 (ICI, 200 nM) to
induce BRAF expression. Western analysis was carried out toassess ERK activation using pERK and ERK antibodies. B. Mouse melanocytes stably expressing
mutant B-RAF were infected with lentiviral vectors carrying shRNA for ATF2 or MITF or both. Cells were plated (5000 per well) on soft agar and assessed for
the ability to form colonies after 21 days using P-Iodonitrotetrazolium Violet staining. Colonies were counted in triplicate wells per experiment, and
experiments were reproduced twice. Means +SD are shown. C. Shown are representative images for quantification depicted in panel B. D. qPCR was
performed for MITF (left panel)a n dA T F 2( middle panel) transcripts using RNA from cells used in panels B/C. Western analysis was performed on lysates
obtainedfromcells usedforcolonyformation withtheindicatedantibodies (rightpanel).E.Mousemelanocytes analyzedforcolony formationwerestained
withBrdU.ThecellcyclephasewasanalyzedusingtheModFitLTv.2program.ThepercentageofcellsinG1,SandG2isshowninthegraph.F.Melanocytes
shown in Panels A–E were also stained with Annexin V (early apoptosis) and 7-AAD (apoptosis and necrosis). The plot presented reveals Annexin-APC
staining on the x-axis and 7-AAD staining on the y-axis. Mean +/2 SD are calculated based on triplicate analyses.
doi:10.1371/journal.pgen.1001258.g006
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PLoS Genetics | www.plosgenetics.org 15 December 2010 | Volume 6 | Issue 12 | e1001258Figure 7. Analysis of nuclear ATF2 and MITF in melanoma specimens using quantitative immunofluorescence. A. ATF2/MITF
expression ratios tended to be higher in metastatic than in primary specimens. B. In the primary specimen cohort, high ATF2/MITF ratios were
associated with decreased 10-year disease specific survival. Quantification was performed by AQUA, which provides continuous output scores. In the
absence of underlying cut-point justification, nuclear ATF2/MITF ratios were randomly binarized by the median ratio for all specimens (primary and
metastatic). Results are shown for the primary cohort only, as no association was found between survival and ATF2/MITF ratios in the metastatic
cases. The number of cases and events (deaths) for high or low ATF2/MITF expression ratios is shown.
doi:10.1371/journal.pgen.1001258.g007
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and mutant CRE-Luc constructs) were obtained from Dr. David
Fisher [58]. pGL3 vectors containing wild-type and BRN2-site-
mutated MITF promoters were obtained from Dr. Colin Goding
[34]. pGL3 vectors containing wild-type and SOX10-site-mutated
MITF promoters were obtained from Dr. Michel Goossens [59].
Retroviral vectors encoding a fusion protein consisting of full
length human BRAF and BRAF
V600E linked to the T1 form of the
human estrogen receptor hormone-binding domain were gener-
ously provided by Dr. Martin McMahon [60]. SOX10 expression
vector obtained from Dr. Alexey Terskikh, RSV-JunB, RSV-JunD
were obtained from Dr. Michael Karin and pBabe-Flag-TAM67
from Dr. Michael Birrer.
Antibodies and immunoblotting
Antibodies against SOX10 and CREB (sc-1734 and sc-186
respectively) were from Santa Cruz Biotechnologies; antibodies
against ATF2, pERK and ERK (catalogue # 9226, 4337 and
4695 respectively) were obtained from Cell Signaling; antibodies
against MITF (C5) were purchased from Cell Lab vision. Protein
extract (40–60 mg) preparation and western blot analysis were
done as described previously [8]. Specific bands were detected
using fluorescent-labeled secondary antibodies (Invitrogen, Carls-
bad, CA) and analyzed using an Odyssey Infrared Scanner (Li-
COR Biosciences). b-Actin antibody was used for monitoring
loading.
Immunofluorescence
Human melanoma and melanocytes were grown in coverslips,
fixed (4% paraformaldehyde and 2% sucrose in 16PBS), and then
permeabilized and blocked (0.4% Triton X-100 and 2% BSA in
16PBS) at room temperature. The cells were then washed (0.2%
Triton X-100 and 0.2% BSA in 16PBS) and incubated overnight
at 4uC with monoclonal anti-rabbit antibody against ATF2 (20F1,
1:100), followed by five washes and then subsequent incubation at
room temperature for 2 h with anti-rabbit IgG (Invitrogen, 1:300)
and Phalloidin (Molecular Probes, 1:1000). DNA was counter-
stained with 4,6-diamidino-2-phenylindole (DAPI; Vector Labo-
ratories) containing mounting medium.
Analysis of skin samples
Skin samples were collected from the backs of mice and
immediately fixed with Z-fix, processed, and embedded in
paraffin. Paraffin sections were routinely stained by H&E.
Dewaxed tissue sections (4.0–5.0 mm) were immunostained using
rabbit polyclonal antibodies to MITF (Sigma-Aldrich), S100
(S100B; DAKOCytomation; Carpinteria, CA), and DCT (aPEP8,
kindly provided by Dr. Vincent Hearing). Application of the
primary antibody was followed by incubation with goat anti-rabbit
polymer-based EnVision-HRP-enzyme conjugate (DakoCytoma-
tion). DAB (DakoCytomation) or SG-Vector (Vector Lab, Inc.;
Burlingame, CA) chromogens were applied, yielding brown (DAB)
and black (SG) colors, respectively.
Quantitative analysis of immunostaining
Quantitative analysis was performed as described previously
[61]. Briefly, all slides were scanned at an absolute magnification
of 4006[resolution of 0.25 mm/pixel (100,000 pix/in.)] using the
Aperio ScanScope CS system (Aperio Technologies; Vista, CA).
The acquired digital images representing whole tissue sections
were analyzed applying the Spectrum Analysis algorithm package
and ImageScope analysis software (version 9; Aperio Technolo-
gies, Inc.) to quantify IHC and histochemical stainings. These
algorithms make use of a color deconvolution method [62] to
separate stains. Algorithm parameters were set to achieve
concordance with manual scoring on a number of high-power
fields, including intensity thresholds for positivity and parameters
that control cell segmentation using the nuclear algorithm.
Microarray analysis
Primary melanocytes were treated with 4-OHT and Doxycy-
cline before isolation of total RNA. 500 ng of total RNA was used
for synthesis of biotin-labeled cRNA using an RNA amplification
kit (Ambion). The biotinylated cRNA is labeled by incubation with
streptavidin-Cy3 to generate probe for hybridization with the
Mouse-6 Expression BeadChip (Illumina MOUSE-6_V1_1_
11234304_A) that represents 46.6K mouse gene transcripts. We
analyzed the BeadChips using the manufacturers BeadArray
Reader and collected primary data using the supplied Scanner
software. Data analysis was done as follows. First, expression
intensities were calculated for each gene probed on the array for
all hybridizations using illumina’s BeadStudio 3.0 software.
Second, intensity values were quality controlled and normalized:
quality control was carried out by using the BeadStudio detection
P-value set to ,0.01 as a cutoff. This removed genes which were
never detected in the arrays. All the arrays were then normalized
using the cubic spline routine from the BeadStudio 3.0 software.
This procedure accounted for any variation in hybridization
intensity between the individual arrays. Finally, these normalized
data were analyzed for differentially expressed genes. The groups
of 2 biological and 2 technical replicates were described to the
BeadStudio 3.0 software and significantly differentially expressed
genes were determined on the basis of the difference changes in
expression level (Illumina DiffScor.60 or DiffScore,260) and
expression difference p-value,0.01. Microarray data are available
under accession number GSE23860.
ShRNA infection and RNA interference
Human embryonic kidney 293T cells were transfected with
corresponding retro- or lentiviral shRNA constructs (10 mg), Gag-
pol (5 mg) and ENV expression vectors (10 mg) by calcium
phosphate transfection into 10 cm plates and supernatant was
collected after 48 hours to obtain viral particles. 2 million
melanocytes and melanoma cells in 10 cm plates were infected
with 5 ml of viral supernatant along with 5 ml of medium in the
presence of 8 mg/ml polybrene. The virus was replaced with fresh
media after 8 hours of infection. After two days, puromycin
(1.5 mg/ml) was used to select cells for 3 days. For human and
mouse melanocytes the media was changed to DMEM containing
10% FBS 24 h prior to harvesting cells. 50 nM duplexes of
scrambled and SOX10- or FOXD3- specific siRNA were
transfected into human melanocytes and WM1361 melanoma
cells (2 million cells per transfection) by Nucleofection using
Amaxa reagents (NHEM-Neo Nucleofector and Solution R
respectively) for SOX10 or FOXD3 knock down. Over 90% of
the cells transduced were able to resist drug selection, indicating
efficient infection of the respective genes. GFP was also used to
monitor efficiency of infection, confirming .90% GFP expression
by fluorescence microscopy.
Real-time quantitative reverse transcription–PCR
(RT–PCR)
Quantitative PCR was performed as described earlier [8]. Total
RNA was isolated using an RNeasy mini kit (Sigma, St. Louis, MO)
and reverse transcribed using a high cDNA capacity reverse
transcription kit (Applied Biosystems, Foster City, CA) following the
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CA) used for PCR were as follows: Human ATF2, forward:
tgtggccagcgttttaccaa, reverse: tgatgtgggctgtgcagttt., human MITF,
forward: aaaccccaccaagtaccaca, reverse: acatggcaagctcaggac., hu-
man SOX10, forward: caa gtaccagcccaggcggc, reverse: gggtgccggtg-
gtccaagtg., human FOXD3, forward: gcgacgggctggaagag, reverse:
gctgtccgtgatggggtgcc., human PAX3, forward: ggaactggagcgtgcttttg,
reverse: ggcggttgctaaaccagac., human BRN2, forward: gaaagagc-
gagcgaggaga, reverse: caggctgtagtggttagacg., mouse MITF, forward:
agatttgagatgctcatcccc,reverse: gatgcgtgatgtcatactgga, mouse TYRP1,
forward: ccctagcctatatctccctttt, reverse: taccatcgtggggataatggc.,
mouse DCT, forward: gtcctccactcttttacagacg, reverse: attcggttgtgac-
caatgggt, mouse Silver, forward: tgacggtggaccctgcccat, reverse:
agctttgcgtggcccgtagc. The reaction mixture was denatured at 95uC
for 10 min, followed by 40 cycles of 95uC for 15s, annealing at 60uC
for 30s and extension at 72uC for 30s. Reactions were performed
using the SYBR Green qPCR reagent (Invitrogen) and run on an
MX3000P qPCR machine (Stratagene, La Jolla, CA). The specificity
of the products was verified by melting curve analysis and agarose
gels. The amount of the target transcript was related to that of a
reference gene (Cyclophilin A for both human and mouse) by the Ct
method. Each sample was assayed at least in triplicate and was
reproduced at least three times.
Chromatin immunoprecipitation
Chromatin immunoprecipitation was performed using the
Magna-Chip (Upstate) according to the manufacturer’s instruc-
tions. Control shRNA and ATF2 knocked down WM1361 cells
(one 10 cm plate for each, 80% confluent) were fixed in 37%
formaldehyde and sheared chromatin was immunoprecipitated
and subjected to PCR for 32 cycles. The following primers
corresponding to the MITF promoter, spanning the SOX10
binding site were used, forward: gcagtcggaagtggcag, reverse:
caactcactgtcagatcaa. Antibodies against Sox10 and CREB (sc-
1734 and sc-186 respectively) were from Santa Cruz Biotechnol-
ogies. IgG control, and glyceraldehyde-3-phosphate dehydroge-
nase oligonucleotides were provided by the kit. Antibody against
ATF2 (sc-6233), JunB (sc-8051), JunD (sc-74) were obtained from
Santa Cruz. Antibodies against ATFa were provided generated by
Nic Jones. For Sox10 promoter, the following primers spanning
AP-1 binding site were used; forward: cccagtgctggcctaatagc,
reverse: cacccttgatatccccaagtga.
Luciferase assays
MeWo, WM35, WM1361, Lu1205 cells in six-well plates
were transiently transfected with 0.5 mg of reporter plasmid
containing WT or CRE mutant, BRN2 mutant or SOX10
mutant MITF promoter and 0.1 mg of pSV-b-Galactosidase
(Promega, San Luis Obispo, CA) using Lipofectamine 2000
reagent (Invitrogen). Human melanocytes (2 million) were
transfected with 2 mg of reporter plasmid containing WT or
SOX10 mutant MITF promoter and 0.3 mgo fp S V - b-
Galactosidase using Amaxa reagent (NHEM-Neo nucleofector
kit, Lonza) according to the manufacturer’s protocol. Cell lysates
were prepared from cells after 48 h. Luciferase activity was
measured using the Luciferase assay system (Promega) in a
luminometer and normalized to b-galactosidase activity. The
data were normalized to b-galactosidase and represent the mean
and SD of assays performed in triplicate. All experiments were
performed a minimum of 3 times.
Colony formation assay
Melan-Ink4a-Arf1 cells were transduced with a retroviral vector
expressing BRAF
V600E:ER
T1 and selected with puromycin for 3
days. These cells were treated with 200 nM of estrogen receptor
antagonist ICI 182780 (ICI, Tocris Bioscience) to induce
expression of BRAF
V600E. After one day, these cells were
transduced with a lentiviral vector expressing either shATF2 or
shMITF separately, or in combination. Colony formation was
carried out as described by Franken et al. [63]. Briefly, 5,000 cells
were plated into each well of a 6-well plate, and cells were grown
in mouse melanocyte media containing ICI and puromycin
(1.5 mg/ml) for 3 weeks until colonies became visible. The colonies
were stained with P-Iodonitrotetrazolium Violet (1 mg/ml Sigma,
St. Louis, MO). This experiment was performed in triplicate and
reproduced 2 times.
Mouse genotyping
Genomic DNA was isolated from tail tissue was subjected to
PCR resulting in amplification of a 549 bp DNA fragment for Atf2
floxed and a 485 bp DNA fragment for wild type mice. PCR
conditions included one cycle at 95uC for 3 min; and 30 cycles of
94uC/30 sec, 55uC/30 sec and 72uC/1 min and one cycle at
72uC for 5 min. Primers used for PCR reactions were forward:
caatccactgccatggcctt, reverse: tcagataaagccaagtcgaatctgg.
Avidin-biotin DNA–protein binding assay
MeWo cells were left untreated or treated with 20 mJ/cm
2 of
UV-B for 1 h. The cells were lysed using lysis buffer containing
1% Triton-100 and incubated with 4 mg of biotin-labeled MITF
promoter spanning the CRE site oligo (59-gaaaaaaaagcatgacgt-
caagccaggggg-39) in the presence of poly-(dI-dC) (20 mg/ml) for 2h
at 4uc. The oligo-bound proteins were captured using streptavidin-
agarose (Invitrogen) for 1 h incubation, followed by extensive
washes with washing buffer (20 mm HEPES, 150 mm NaCl, 20%
glycerol, 0.5 mm EDTA, and 1% Triton-100) and analyzed using
SDS-PAGE and western blots.
BrdU, PI labeling, Annexin V staining
To evaluate the cell cycle index of Melan-Ink4a-Arf1 cells stably
overexpressing BRAF
V600E:ER
T1 alone or in combination with
shRNA to the genes indicated in Results, cells were plated in
media containing ICI and puromycin (1.5 mg/ml) at 2610
6 cells
per 10 cm plate O/N. Cells were labeled with 10 mM of 5-bromo-
2-deoxyuridine (BrdU; Sigma Chemical Co.), for an hour. Cells
were then washed, fixed, and stained with anti-BrdU mAbs and
propidium Iodide (BD Biosciences, San Jose, CA) according to the
manufacturer’s protocol, and analyzed on a BD FACSCanto
machine. Cell cycle phase was analyzed using the Mod Fit LT v.2
program (Verity Software, Topsham, ME). In a separate
experiment the cells were stained with Annexin V-APC and 7-
AAD (BD Pharmingen, San Diego, CA) according to manufac-
turer’s protocol, to enable analysis of early apoptosis and cell
death.
Hypoxia treatment
Cells were treated under hypoxia (1% O2) for indicated time
points using a hypoxia chamber (In Vivo 400; Ruskin Technol-
ogies Ltd, Bridgend, UK).
UV irradiation
Mice were treated with 4-Hydroxytamoxifen (25 mg/ml in
DMSO) by swabbing the entire body (excluding the head) on days
1–3 after birth. On day 4 the pups were placed under UVB light
source (FL-15E; 320 nm) and exposed to 20 mW/cm
2 for
22 seconds. Ninety minutes after UVB treatment mice were
sacrificed and entire skin was removed and processed.
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Tissue microarrays were constructed as previously described
[21]. The arrays included a series of 192 sequentially collected
primary melanomas and 299 metastatic melanomas. Slides were
stained for automated, quantitative analysis (AQUA) for ATF2
and MITF as previously published [49,64]. The AQUA scores for
the two markers were obtained from the AQUAmine database
(www.tissuearray.org).
Supporting Information
Figure S1 Representative staining of non-melanoma tumor
developed in the TyrCre
+::Atf2
+/+::Nras
Q61K::Ink4a
2/2 model.
Found at: doi:doi:10.1371/journal.pgen.1001258.s001 (7.25 MB
TIF)
Figure S2 A. ATF2 negatively regulates MITF in several
melanoma lines. ATF2 was knocked down in WM793 cells (left
panel), in WM35 cells (middle panel) and in WM1361 cells (right panel)
(one 10 cm plate each, 50% confluent). Cells were lysed and
Western blotting was carried out (50 mg/lane) with the indicated
antibodies. Lower panel, RNA was extracted from the correspond-
ing cell lines, and qPCR was carried out using MITF primers.
Cyclophilin A was served as an internal control. B. ATF2
positively regulates MITF in 501-MEL melanoma cells. Left panel,
ATF2 was knocked down in 501- Mel cells (one 10 cm plate each,
50% confluent). Cells were lysed and Western blotting was carried
out (40 mg/lane) with the indicated antibodies. Right panel, RNA
was extracted from the above samples and qPCR was carried out
using MITF primers; Cyclophilin A served as an internal control.
Found at: doi:doi:10.1371/journal.pgen.1001258.s002 (1.36 MB
TIF)
Figure S3 A. ATF2 effect on Brn2 and Pax3 in human
melanocytes and melanoma cells. Cells were infected with shRNA
control or shATF2 and RNA prepared was used for qPCR
analysis of Pax3 and Brn2 expression, relative t o cyclophilin used
as control. B. Increased SOX10 mRNA expression in melanoma
cells. ATF2 expression was inhibited in WM1361 cells and total
mRNA was extracted. A qPCR was performed to quantify
changes in the expression of the indicated genes. Cyclophilin A
served as an internal control.
Found at: doi:doi:10.1371/journal.pgen.1001258.s003 (0.93 MB
TIF)
Figure S4 Effect of ATF2 and FoxD3 on Sox10 and MITF
expression in human melanocytes. H3a human melanocytes cells
were infected with Scrambled Control siRNA (siSC), shATF2,
siFOXD3 or their combination. Protein or RNA were prepared
72h later and assessed in western and qPCR.
Found at: doi:doi:10.1371/journal.pgen.1001258.s004 (1.16 MB
TIF)
Figure S5 Analysis of ATF2 effect on SOX10 and MITF
transcription in 12 melanoma cell lines. Melanoma cell lines
indicated were infected with shATF2 and subjected to selection to
enrich for ATF2 KD cells. RNA was prepared 4 days later and
QPCR analysis was performed for ATF2 (upper panel), MITF
(middle panel) and SOX10 (lower panel) transcripts. Data shown
represent analysis of triplicate samples.
Found at: doi:doi:10.1371/journal.pgen.1001258.s005 (1.70 MB
TIF)
Figure S6 Altered MITF expression by ATF2 +/2 SOX10 in
human melanocytes and melanomas. Indicated cell lines were
infected with shControl or shATF2, in the presence or absence of
SOX10 overexpression, and proteins were prepared to determine
changes in expression of SOX10. b-actin was used as loading
control. Analysis of MITF and SOX10 transcript levels was
carried out in the indicated cell lines using qPCR on RNA
prepared from the cells that were infected with indicated vectors
(C, C+SOX10, shATF2, shATF2+SOX10).
Found at: doi:doi:10.1371/journal.pgen.1001258.s006 (2.59 MB
TIF)
Figure S7 Effect of ATF2 on SOX10 and MITF in human
melanoma cell lines exhibiting positive regulation by ATF2. A.
Melanoma cell lines MeWo and 501Mel were infected with
shControl or shATF2 and level of SOX10 protein was assessed. B,
C. The effect of SOX10 expression on MITF (B) and on SOX10
(C) transcripts in MeWO (left graph) cells expressing control or
shATF2 was determined using qPCR. D. Effect of DN Jun and
JunB on SOX10 protein and MITF transcript levels. Indicated
melanoma cells were transfected with TAM67 (DN Jun) and
JUNB either alone or in combination as indicated. The cells were
lysed and proteins and RNA were prepared. Western blotting was
carried out with the indicated antibodies. QPCR analysis for
MITF transcripts was performed (lower panel). E. Chromatin IP
reveals loss of JunB binding to SOX10 promoter in melanoma
cells in which MITF is positively regulated by ATF2. Melanoma
cells were subjected to ChIP using the indicated antibodies
followed by PCR of SOX10 promoter sequences harboring the
AP1 response element. F. Endogenous level of JUNB in various
melanoma cells. Cell lysates from indicated melanoma cells were
subjected to Western blot analysis using JUNB antibody. b–actin
was used as a loading control.
Found at: doi:doi:10.1371/journal.pgen.1001258.s007 (1.06 MB
TIF)
Figure S8 A. Transcriptional activity of MITF is dependent on
ATF2 and a CRE element in specific melanoma cells that express
high MITF levels. WT and mutant (CRE) forms of MITF-Luc
constructs were used to assess the contribution of ATF2 to MITF
transcription in MeWo cells. Luciferase assays were performed as
detailed in Materials and Methods. B. ATF2 and CREB bind to a
MITF CRE site. Human melanoma (MeWo) cells were treated
with 20mJ/cm
2 of UVB, and proteins prepared after 1h were
incubated with dI/dT (20 mg/ml for 30 min at 4C) and then with
a biotinylated annealed oligo (4 mg, overnight at 4uC) containing
the CRE site and flanking sequences from the MITF promoter.
Streptavidin beads were added to lysates and bound material was
analyzed on immunoblots with the indicated antibodies. C. ChIP
analysis shows ATF2 binding to the MITF CRE site in specific
melanoma MeWo cells. Chromatin was prepared and precipitated
using an ATF2 antibody and bound DNA was amplified using
MITF specific primers that flank the CRE binding site and
analyzed on 1.5% agarose gel. Rabbit IgG served as a negative
control and CREB and ATF1 served as positive controls.
Found at: doi:doi:10.1371/journal.pgen.1001258.s008 (1.34 MB
TIF)
Figure S9 Subcellular localization of ATF2 in melanoma cell
lines. Immunostaining was carried out in indicated melanoma and
human melanocyte cells with ATF2 (green) antibody and
Phalloidin (red). The cells were counter stained with DAPI for
nuclear staining.
Found at: doi:doi:10.1371/journal.pgen.1001258.s009 (6.98 MB
TIF)
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